Milestones

Share this page

Milestones

2017

QuantiFERON-TB  Gold Plus gains regulatory approval from the U.S.Food and Drug Administration. QFT-Plus represents the fourth generation of the market leading blood test for detecting latent tuberculosis (TB) infection.

GeneReader NGS System gains momentum in next-generation sequencing with enhanced technology, favorable user experience and new gene panels.

QIAGEN acquires OmicSoft Corporation, with software enabling customers to better manage genomic data and compare findings against massive public data sets.

2016

SALES: $1.34 BN EMPLOYEES: 4,700

Screening with QuantiFERON-TB accelerates rapidly as the global fight against tuberculosis adopts early warning strategy of finding and treating latent TB.

QIAGEN’s end-to-end GeneReader NGS System captures 10% of market for new benchtop sequencers in oncology.

New core technologies serve fast-growing fields of liquid biopsies, single cells and microbiomes.

QIAGEN acquires Exiqon A/S, adding solutions to unlock insights from RNA in the fight against cancer and other diseases.

2015

SALES: $1.28 BN EMPLOYEES: 4,600

QIAGEN launches the GeneReader NGS System, the first complete Sample to Insight solution designed for any lab to deliver actionable insights.

With the launch of new genetic fingerprinting kits for forensic labs, QIAGEN is the first new entrant in more than 20 years in the U.S. market for STR test kits.

In Europe, QIAGEN receives the first-ever regulatory registration of a lung cancer companion diagnostic based on liquid biopsies.

Launch of QuantiFERON-TB Gold Plus, the fourth-generation of QIAGEN’s industry-leading test for tuberculosis (TB) infection.

GeneReader Workflow

The GeneReader NGS System launched in late 2015 as the world's first truly complete NGS workflow.

2014

NET SALES: $1.35 BN EMPLOYEES: 4,300

With the acquisition of Enzymatics and launch of 14 new gene panels, QIAGEN further strengthens its offering of universal solutions for next-generation sequencing.

QIAGEN’s technologies play a key role in the fight against the devastating Ebola outbreak in Africa.

The U.S. Food and Drug Administration grants regulatory clearance for the QIAsymphony RGQ MDx, marking a milestone for QIAGEN’s global rollout of its flagship automation platform.

In line with its strategy to address the rapidly growing needs of customers to transform biological samples into valuable molecular insights, QIAGEN establishes the business area Bioinformatics. 

2013

NET SALES: $1.30BN EMPLOYEES: 4,000

QIAGEN acquires Ingenuity Systems and CLC Bio, creating leadership in solutions for analysis and interpretation of biological data.

The FDA approves QIAGEN’s therascreen EGFR test as a companion diagnostic for Gilotrif in patients with non-small cell lung cancer. 

2012

NET SALES: $1.26BN EMPLOYEES: 4,000

QIAGEN gains FDA approval for its KRAS test as companion diagnostic for Erbitux in metastatic colorectal cancer patients and achieves a milestone in personalized healthcare.

Start of a comprehensive initiative to develop complete next-generation sequencing workflow solutions for clinical applications.

QIAGEN restructures the company with the creation of two Business Areas – "Life Sciences" and "Molecular Diagnostics". 

KRAS test tube

The FDA approval for QIAGEN's therascreen KRAS emphasized the company's leading position in personalized healthcare.

2011

NET SALES: $1.17BN EMPLOYEES: 3,900

Acquisition of QuantiFERON technology that allows for the detection of many diseases far earlier than other methods.

QIAGEN acquires a majority stake in the French company Ipsogen and gains access to a leading portfolio of blood cancer tests.

Further expansion in Asia with new subsidiaries in India and Taiwan. 

2010

NET SALES: $1.09BN EMPLOYEES: 3,600

QIAGEN acquires a new detection technology for Point of Need. The instruments are highly affordable, portable and generate results in 5 to 15 minutes.

This technology plays a key role in a pilot project run by the UN Food and Agriculture Organization and the International Atomic Energy Agency to contain animal diseases in emerging countries.

QIAGEN launches QIAsymphony RGQ, a highly flexible modular automation platform covering entire laboratory workflows.

QIAsymphony

Thanks to its flexibility and growing menu of applications, the QIAsymphony has rapidly become one of the most popular lab automation platforms in the market.

2009

NET SALES: $1.01BN EMPLOYEES: 3,400

QIAGEN enhances its portfolio with several PCR-based assay panels covering entire biological pathways and diseases, thereby strengthening its offering for pharmaceutical research.

QIAGEN acquires DxS Ltd., giving the company a leadership position in personalized healthcare.

QIAGEN’s technologies play a key role in the fight against the global Swine Flu pandemic.

With the real-time PCR cycler Rotor-Gene Q and QIAgility for automated assay setup, QIAGEN enables the automation of complete laboratory workflows from sample to result. 

2008

NET SALES: $893M EMPLOYEES: 3,000

Acquisition of Pyrosequencing, a detection technology that works on a single base-pair level and allows the identification of unknown DNA sequences or mutations. QIAsymphony SP launches as the first system in a series of modular instruments, designed to automate entire laboratory workflows.

2007

NET SALES: $650M EMPLOYEES: 2,600

QIAGEN merges with Digene Corp., creating the market and technology leader in molecular diagnostics.

QIAGEN introduces QIAcube, a revolutionary platform which fully automates the processing of QIAGEN consumable products. 

QIAGEN Gaithersburg

The acquisition of Digene for $1.6 billion significantly contributed to QIAGEN's expansion in molecular diagnostics.

2006

Net sales: $466m Employees: 1,800

QIAGEN acquires an assay technology which allows for the testing of multiple pathogens in a single run (“multiplexing”).

QIAGEN establishes its Asia regional headquarters in Shanghai. 

2005

NET SALES: $398M EMPLOYEES: 1,600

QIAGEN acquires a leading position in molecular diagnostics by adding various PCR-based molecular tests to its portfolio.

Development of the artus influenza kit for the rapid detection of all known variants of the Avian Flu virus H5N1.

QIAGEN receives the world’s first governmental clearance for an Avian Flu assay (through its subsidiary PG Biotech in China).

QIAGEN launches the first human whole genome siRNA set worldwide. siRNAs are molecules that can shut down the activity of individual genes. 

Rotor-Gene Q Disc

QIAGEN's current product portfolio includes dozens of various PCR tests and corresponding reagents for applications in molecular diagnostics, applied testing and life sciences research.

2004

NET SALES: $380M EMPLOYEES: 1,300

QIAGEN’s QIAamp becomes the world’s first standalone product for sample preparation to receive the CE-mark.

2002

NET SALES: $298M EMPLOYEES: 1,600

Relocation of US headquarters from Valencia, CA, to Germantown, MD. 


2001

NET SALES: $263M EMPLOYEES: 1,550

QIAGEN launches PAXgene, the first product that consolidates and integrates key steps of sample collection, stabilization and purification. 

PAXgene cfDNA blood tubes

Today, the PAXgene product line covers a broad range of sample types including tissue, blood and bone marrow. 

1999

NET SALES: $158M EMPLOYEES: 900

PreAnalytiX, a joint venture with Becton, Dickinson and Company, is established. 

 

1998

NET SALES: $120M EMPLOYEES: 800

QIAGEN significantly expands its capabilities in automation.

 

QIAsymphony assembly

The acquisition of Rosys AG in 1998 marked an important milestone in the development of QIAGEN to a provider of integrated workflow solutions for molecular laboratories. 

1997

NET SALES: $75M EMPLOYEES: 600

Initial Public Offering is completed on Deutsche Boerse, Frankfurt. 

 

1996

NET SALES: $54M EMPLOYEES: 450

QIAGEN N.V. (Holding) established in Venlo, The Netherlands.

Initial Public Offering is completed on NASDAQ, New York.

QIAGEN introduces the BioRobot 9600, its first bench-top workstation, which automates purification technologies. 

QIAGEN Stock Certificate

On June 28, 1996, the letters QGEN crawled over a stock market ticker for the first time. The IPO allowed QIAGEN to fund its ambitious international growth strategy.

1986

NET SALES: $100,000 EMPLOYEES: 5

QIAGEN revolutionizes molecular biology by introducing the first "Plasmid-Kit". It reduces the time needed for the preparation of plasmids, ring-shaped DNA molecules from bacteria, from 2-3 days to 2 hours.

1984

NET SALES: $0 EMPLOYEES: 2

QIAGEN (Diagen) is founded in Düsseldorf, Germany.


SOCIAL SHARING